Erythrocyte sedimentation rate - Possible role in determining the existence of the low grade inflammation in Irritable Bowel Syndrome patients

Medical Hypotheses

Volumn 78, Issue 6, 2012, Pages 818-820

  Hauser, Goran ^a   Tkalcic, Mladenka ^b   Pletikosic, Sanda ^b   Grabar, Nina ^b   Stimac, Davor ^a  

^a KBC RIJEKA   (Croatia)

^b Filozofskog fakulteta u Rijeci   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DISEASE SEVERITY; EMOTIONAL DISORDER; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HYPOTHESIS; INFLAMMATION; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PILOT STUDY; QUALITY OF LIFE; SOCIAL DISABILITY;

ADULT; BLOOD SEDIMENTATION; CROATIA; FEMALE; HUMANS; INFLAMMATION; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE;

EID: 84860359764     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.03.020     Document Type: Article

References (37)

1. El-Serag H.B., Olden K., Bjorkman D. Health-related quality of life among persons with Irritable Bowel Syndrome: a systematic review. Aliment Pharmacol Ther 2002, 16(6):1171-1185.
2. Thompson W.G., Heaton K.W., Smyth G.T., Smyth C. Irritable Bowel Syndrome in general practice: prevalence, characteristics, and referral. Gut 2000, 46(1):78.
3. American College of Gastroenterology Task Force on Irritable Bowel Syndrome. An evidence based systematic review on the management of Irritable Bowel Syndrome. Am J Gastroenterol 2009;104(Suppl. 1):S1-S35.
4. Wong E., Guyatt G.H., Cook D.J., Griffith L.E., Irvine E.J. Development of a questionnaire to measure quality of life in patients with Irritable Bowel Syndrome. Eur J Surg Suppl 1998, 583:50-56.
5. öhman L., Simrén M. New insights into the pathogenesis and pathophysiology of Irritable Bowel Syndrome. Dig Liver Dis 2007, 39(3):201-215.
6. Gwee K.A. Post-infectious Irritable Bowel Syndrome, an inflammation-immunological model with relevance for other IBS and functional dyspepsia. J Neurogastroenterol Motil 2010, 16(1):30-34.
7. Clarke G., Quigley E.M., Cryan J.F., Dinan T.G. Irritable Bowel Syndrome: towards biomarker identification. Trends Mol Med 2009, 15(10):478-489.
8. öhman L., Isaksson S., Lundgren A., Simrén M., Sjövall H. A controlled study of colonic immune activity and β7+ blood T lymphocytes in patients with Irritable Bowel Syndrome. Clin Gastroenterol Hepatol 2005, 3(10):980-986.
9. Spiller R., Garsed K. Post-infectious Irritable Bowel Syndrome. Gastroenterology 2009, 136(6):1979-1988.
10. Spiller R., Garsed K. Infection, inflammation, and the Irritable Bowel Syndrome. Dig Liver Dis 2009, 41(12):844-849.
11. Elsenbruch S. Abdominal pain in Irritable Bowel Syndrome: a review of putative psychological, neural and neuro-immune mechanisms. Brain Behav Immun 2011, 25(3):386-394.
12. Reichenberg A., Yirmiya R., Schuld A., et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001, 58(5):445-452.
13. Capuron L., Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004, 56(11):819-824.
14. Zahn A., Hinz U., Karner M., Ehehalt R., Stremmel W. Health related quality of life correlates with clinical and endoscopic activity indexes but not with demographic features in patients with ulcerative colitis. Inflamm Bowel Dis 2006, 12(11):1058-1067.
15. Minderhoud I.M., Oldenburg B., Wismeijer J.A., van Berge Henegouwen G.P., Smout A.J. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behaviour. Dig Dis Sci 2004, 49(3):469-474.
16. Malinen E., Rinttilä T., Kajander K., Mättö J., Kassinen A., Krogius L., et al. Analysis of the fecal microbiota of Irritable Bowel Syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005, 100(2):373-382.
17. Mättö J., Maunuksela L., Kajander K., et al. Composition and temporal stability of gastrointestinal microbiota in Irritable Bowel Syndrome - a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005, 43(2):213-222.
18. Keohane J., O'Mahony C., O'Mahony L., O'Mahony S., Quigley E.M., Shanahan F. Irritable Bowel Syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?. Am J Gastroenterol 2010, 105(8):1788-1794.
19. Lettesjö H., Hansson T., Peterson C., et al. Detection of inflammatory markers in stools from patients with Irritable Bowel Syndrome and collagenous colitis. Scand J Gastroenterol 2006, 41(1):54-59.
20. Kaiser T., Langhorst J., Wittkowski H., et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from Irritable Bowel Syndrome. Gut 2007, 56(12):1706-1713.
21. Schoepfer A.M., Trummler M., Seeholzer P., Seibold-Schmid B., Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008, 14(1):32-39.
22. Drossman D., Morris C.B., Hu Y., et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol 2007, 102:1442-1453.
23. Hahn B.A., Kirchdoerfer L.J., Fullerton S., Mayer E. Evaluation of a new Quality of Life Questionnaire for patients with Irritable Bowel Syndrome. Aliment Pharmacol Ther 1997, 11:547-552.
24. Ware J.E., Sherbourne C.D. 36-Item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
25. Paddison J.S., Booth R.J., Fuchs D., Hill A.G. Peritoneal inflammation and fatigue experiences following colorectal surgery: a pilot study. Psychoneuroendocrinology 2008, 33(4):446-454.
26. Schubert C., Hong S., Natarajan L., Mills P.J., Dimsdale J.E. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 2007, 21(4):413-427.
27. Macsharry J., O'Mahony L., Fanning A., et al. Mucosal cytokine imbalance in Irritable Bowel Syndrome. Scand J Gastroenterol 2008, 43(12):1467-1476.
28. Ansari R., Attari F., Razjouyan H., et al. Ulcerative colitis and Irritable Bowel Syndrome: relationships with quality of life. Eur J Gastroenterol Hepatol 2008, 20(1):46-50.
29. Spiller R.C., Jenkins D., Thornley J.P., et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric Irritable Bowel Syndrome. Gut 2000, 47(6):804-811.
30. Gwee K.A., Collins S.M., Read N.W., et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious Irritable Bowel Syndrome. Gut 2003, 52(4):523-526.
31. Guilarte M., Santos J., de Torres I., et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007, 56(2):203-209.
32. O'Mahony L., McCarthy J., Kelly P., et al. Lactobacillus and bifidobacterium in Irritable Bowel Syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128(3):541-551.
33. Levy R.L., Olden K.W., Naliboff B.D., et al. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology 2006, 130(5):1447-1458.
34. Dunlop S.P., Jenkins D., Neal K.R., Spiller R.C. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in post-infectious IBS. Gastroenterology 2003, 125(6):1651-1659.
35. Tkalčić M., Hauser G., Stimac D. Differences in the health-related quality of life, affective status, and personality between Irritable Bowel Syndrome and inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2010, 22(7):862-867.
36. Barbara G., Stanghellini V., Cremon C., et al. Aminosalicylates and other anti-inflammatory compounds for Irritable Bowel Syndrome. Dig Dis 2009, 27(Suppl. 1):115-121.
37. Lembo A.J., Neri B., Tolley J., Barken D., Carroll S., Pan H. Use of serum biomarkers in a diagnostic test for Irritable Bowel Syndrome. Aliment Pharmacol Ther 2009, 29(8):834-842.